Nyxoah S A (NYXH) Stock Price, Quote & News

Company Profile

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 32 1 022 23 55

Fax: 32 1 045 90 75

Website: www.nyxoah.com

Address:

Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium

HoneyHedge Dec. 25 at 9:25 AM

$NYXH The valuation debate now centers on reliability of delivery, with macro volatility magnifying operational missteps. Momentum turns durable only after multiple confirmations.

0 · Reply

JohnTrack Dec. 19 at 9:15 PM

$NYXH Commercial Launch of Genio® Breakthrough Therapy in the Netherlands https://www.rapidticker.com/news/nyxh-sec-filing-8e3bc6

0 · Reply

SuperGreenToday Dec. 19 at 6:10 PM

$NYXH

0 · Reply

OpenOutcrier Dec. 17 at 2:00 PM

$NYXH (+6.0% pre) New battery-free sleep apnea implant debuts in Dutch hospitals https://ooc.bz/l/87759

0 · Reply

islandpunk Dec. 17 at 6:50 AM

$NYXH https://www.stocktitan.net/news/NYXH/nyxoah-announces-commercial-launch-of-genio-breakthrough-therapy-in-l4glybk0sir9.html

0 · Reply

ZacksResearch Dec. 1 at 2:33 PM

$NYXH down 40% so far this year but could a CMS reimbursement boost improve prospects in 2026? 🔄 🩺 CPT Code 64568 rates up 48% for hospitals and 58% for ASCs in 2026 💸 New rates could drive adoption and expand Medicare-heavy institutions See how this could impact NYXH's future here 👉 https://www.zacks.com/stock/news/2797639/nyxoah-gains-favorable-cms-reimbursement-ruling-for-genio-system?cid=sm-stocktwits-2-2797639-body-22848&ADID=SYND_STOCKTWITS_TWEET_2_2797639_BODY_22848

0 · Reply

ZacksResearch Dec. 1 at 1:33 PM

Big win for $NYXH — this CMS ruling could be a real momentum catalyst. The finalized 2026 reimbursement for its Genio implants jumps sharply, giving its OSA therapy a much stronger commercial runway. See what this means for the setup 👉 https://www.zacks.com/stock/news/2797639/nyxoah-gains-favorable-cms-reimbursement-ruling-for-genio-system?cid=sm-stocktwits-2-2797639-teaser-22846&ADID=SYND_STOCKTWITS_TWEET_2_2797639_TEASER_22846

0 · Reply

mikesterz7 Nov. 26 at 1:38 PM

$NYXH Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

0 · Reply

StocktwitsNews Nov. 26 at 1:29 PM

Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy $NYXH $BMED $INSP https://stocktwits.com/news/equity/markets/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB

0 · Reply

mebanks Nov. 26 at 11:47 AM

$NYXH , some good news here as well "Effective January 1, 2026, Hospital Outpatient Department (HOPD) reimbursement for CPT 64568 will increase to approximately $45,000, a 48% rise compared to 2025. In addition, Ambulatory Surgery Centers (ASC) facility reimbursement will increase to $42,373, reflecting a 58% increase compared to 2025." Be careful as this prospectus for 1.2M shares was updated 9 days ago https://www.sec.gov/Archives/edgar/data/1857190/000110465925112911/tm2531378-1_424b5.htm

0 · Reply

Nyxoah Announces Issuance of First Tranche of Convertible Bonds

Dec 17, 2025, 1:05 AM EST - 8 days ago

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

Dec 2, 2025, 4:30 PM EST - 22 days ago

Publication relating to transparency notifications

Nov 27, 2025, 4:05 PM EST - 27 days ago

Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 1:45 AM EST - 4 weeks ago

Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Nov 20, 2025, 4:30 PM EST - 4 weeks ago

Information on the total number of voting rights and shares

Nov 13, 2025, 9:01 PM EST - 5 weeks ago

Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:36 PM EST - 5 weeks ago

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Nov 13, 2025, 4:12 PM EST - 5 weeks ago

Nyxoah Reports Third Quarter 2025 Financial and Operating Results

Nov 3, 2025, 4:05 PM EST - 7 weeks ago

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

Oct 30, 2025, 5:10 PM EDT - 7 weeks ago

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

Oct 6, 2025, 1:00 AM EDT - 2 months ago

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System

Sep 23, 2025, 4:10 PM EDT - 3 months ago

Nyxoah Provides an Update on Expanded Middle East Presence

Sep 15, 2025, 4:10 PM EDT - 3 months ago

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

Sep 10, 2025, 2:50 AM EDT - 3 months ago

Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 4:30 PM EDT - 4 months ago

Nyxoah Announces Upcoming Investor Events

Aug 20, 2025, 8:00 AM EDT - 4 months ago

Nyxoah: High-Risk High-Reward Medtech To Own

Aug 18, 2025, 7:07 PM EDT - 4 months ago

Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript

Aug 18, 2025, 4:10 PM EDT - 4 months ago

Nyxoah Reports Second Quarter Financial and Operating Results

Aug 11, 2025, 1:00 AM EDT - 4 months ago

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Aug 8, 2025, 4:10 PM EDT - 4 months ago

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

Jul 29, 2025, 4:30 PM EDT - 5 months ago

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

Jul 28, 2025, 4:05 PM EDT - 5 months ago

Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

Jun 13, 2025, 1:00 AM EDT - 6 months ago

Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025

May 28, 2025, 4:30 PM EDT - 7 months ago

Nyxoah to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 2:35 PM EDT - 8 months ago

Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:00 AM EDT - 8 months ago

Nyxoah Reports First Quarter Financial and Operating Results

May 9, 2025, 1:00 AM EDT - 8 months ago

Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025

Apr 22, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Shareholders to Reach Out

Apr 21, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Shareholders to Learn More About the Investigation

Apr 20, 2025, 10:00 AM EDT - 8 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 18, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Shareholders to Inquire about Securities Investigation

Apr 17, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to Connect

Apr 16, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Stockholders to Inquire about Securities Investigation

Apr 16, 2025, 2:00 AM EDT - 9 months ago

Conditional Issuance of Shares

Apr 15, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Investors to Learn More About the Investigation

Apr 14, 2025, 10:00 AM EDT - 9 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 11, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Stockholders to Connect

Apr 10, 2025, 10:00 AM EDT - 9 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 9, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Stockholders to Learn More About the Investigation

Apr 8, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Investors to Inquire about Securities Investigation

Apr 8, 2025, 1:00 AM EDT - 9 months ago

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Apr 7, 2025, 3:00 PM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Investors to Reach Out

Apr 7, 2025, 9:33 AM EDT - 9 months ago

NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm

Mar 31, 2025, 5:40 PM EDT - 9 months ago

Nyxoah S.A. Investors: Company Investigated by the Portnoy Law Firm

Mar 31, 2025, 2:45 PM EDT - 9 months ago

Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A.

HoneyHedge Dec. 25 at 9:25 AM

$NYXH The valuation debate now centers on reliability of delivery, with macro volatility magnifying operational missteps. Momentum turns durable only after multiple confirmations.

0 · Reply

JohnTrack Dec. 19 at 9:15 PM

$NYXH Commercial Launch of Genio® Breakthrough Therapy in the Netherlands https://www.rapidticker.com/news/nyxh-sec-filing-8e3bc6

0 · Reply

SuperGreenToday Dec. 19 at 6:10 PM

$NYXH

0 · Reply

OpenOutcrier Dec. 17 at 2:00 PM

$NYXH (+6.0% pre) New battery-free sleep apnea implant debuts in Dutch hospitals https://ooc.bz/l/87759

0 · Reply

islandpunk Dec. 17 at 6:50 AM

$NYXH https://www.stocktitan.net/news/NYXH/nyxoah-announces-commercial-launch-of-genio-breakthrough-therapy-in-l4glybk0sir9.html

0 · Reply

ZacksResearch Dec. 1 at 2:33 PM

0 · Reply

ZacksResearch Dec. 1 at 1:33 PM

0 · Reply

mikesterz7 Nov. 26 at 1:38 PM

$NYXH Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

0 · Reply

StocktwitsNews Nov. 26 at 1:29 PM

0 · Reply

mebanks Nov. 26 at 11:47 AM

0 · Reply

xyzxyzxyz1978 Nov. 25 at 6:22 AM

$NYXH uses the same CPT code as $INSP.

0 · Reply

Noobnr1 Nov. 18 at 3:55 PM

$NYXH 🚀💎🚀 C’mon

0 · Reply

JarvisFlow Nov. 14 at 4:15 PM

Piper Sandler has updated their rating for Nyxoah ( $NYXH ) to Overweight with a price target of 9.

0 · Reply

Pacho_Unlimited1 Nov. 13 at 9:28 PM

$NYXH GREAT NUMBERS!

0 · Reply

Noobnr1 Nov. 13 at 4:15 PM

$BEAM C’mon let’s go again thanks $PFE $NYXH numbers after hours 🚀🚀🚀 $PHAR 🥇🐇

0 · Reply

TheVirus0011 Nov. 13 at 12:54 PM

$NYXH results today

0 · Reply

Noobnr1 Nov. 10 at 5:28 PM

$NYXH 🚀💎 $PHAR 🐇🚀 $DVAX 🚀🤞 C’mon big ones $GILD and $PFE 🙏🙏

0 · Reply

TheVirus0011 Oct. 27 at 3:34 PM

$TNXP it's time to fly $LASE $PSTV $TLRY $NYXH

0 · Reply

Culby Oct. 24 at 6:37 PM

$NYXH anyone alive on this board??

0 · Reply

Culby Oct. 15 at 3:50 PM

$NYXH why is this dropping back down?

0 · Reply

TheVirus0011 Oct. 13 at 6:27 PM

$PSTV Good evening, some people are talking about November 13-14-15 for the results, on Trading View they say in 3 days, when will the results actually come out? $HUMA $LASE $NYXH

2 · Reply

TheVirus0011 Oct. 10 at 6:44 PM

$PSTV Hello, I'm from Belgium. I can't figure out why the market is bright red and the VIX is soaring. Can someone tell me in the comments, please? $NYXH $LASE $HUMA

3 · Reply

Market Cap	158.72M
Revenue (ttm)	4.89M
Net Income (ttm)	-64.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,310.84%
Debt to Equity Ratio	0.37

Volume	3,000
Avg Vol	38,112
Day's Range	N/A - N/A
Shares Out	34.06M
Stochastic %K	19%
Beta	1.55
Analysts	Strong Sell
Price Target	$11.25